Randomised clinical study: GR-MD-02, a galectin-3 inhibitor, vs. placebo in patients having non-alcoholic steatohepatitis with advanced fibrosis
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Randomised clinical study: GR-MD-02, a galectin-3 inhibitor, vs. placebo in patients having non-alcoholic steatohepatitis with advanced fibrosis
Authors
Keywords
-
Journal
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
Volume 44, Issue 11-12, Pages 1183-1198
Publisher
Wiley
Online
2016-10-25
DOI
10.1111/apt.13816
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Unknown
- (2015) Ilija Jeftic et al. MOLECULAR MEDICINE
- Review article: the efficacy of biomarkers in chronic fibroproliferative diseases - early diagnosis and prognosis, with liver fibrosis as an exemplar
- (2014) M. A. Karsdal et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- CONSORT 2010 Statement: Updated Guidelines for Reporting Parallel Group Randomized Trials
- (2013) Kenneth F. Schulz ANNALS OF INTERNAL MEDICINE
- Slow regression of liver fibrosis presumed by repeated biomarkers after virological cure in patients with chronic hepatitis C
- (2013) Thierry Poynard et al. JOURNAL OF HEPATOLOGY
- Therapy of Experimental NASH and Fibrosis with Galectin Inhibitors
- (2013) Peter G. Traber et al. PLoS One
- Regression of Fibrosis and Reversal of Cirrhosis in Rats by Galectin Inhibitors in Thioacetamide-Induced Liver Disease
- (2013) Peter G. Traber et al. PLoS One
- Alpha-2-macroglobulin: A physiological guardian
- (2012) Ahmed A. Rehman et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Validation of liver fibrosis biomarker (FibroTest) for assessing liver fibrosis progression: Proof of concept and first application in a large population
- (2012) Thierry Poynard et al. JOURNAL OF HEPATOLOGY
- Deficiency in Galectin-3 Promotes Hepatic Injury in CDAA Diet-Induced Nonalcoholic Fatty Liver Disease
- (2012) Kazuhiro Nomoto et al. TheScientificWorldJOURNAL
- Regulation of Transforming Growth Factor-β1–driven Lung Fibrosis by Galectin-3
- (2011) Alison C. MacKinnon et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- When Galectins Recognize Glycans: From Biochemistry to Physiology and Back Again
- (2011) Santiago Di Lella et al. BIOCHEMISTRY
- Serum galectin-3 levels in patients with nonalcoholic fatty liver disease
- (2011) Yusuf Yilmaz et al. CLINICAL BIOCHEMISTRY
- High-fructose, medium chain trans fat diet induces liver fibrosis and elevates plasma coenzyme Q9 in a novel murine model of obesity and nonalcoholic steatohepatitis
- (2010) Rohit Kohli et al. HEPATOLOGY
- Serum Galectin-3 Is Elevated in Obesity and Negatively Correlates with Glycosylated Hemoglobin in Type 2 Diabetes
- (2010) Johanna Weigert et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Galectin-3 ablation protects mice from diet-induced NASH: A major scavenging role for galectin-3 in liver
- (2010) Carla Iacobini et al. JOURNAL OF HEPATOLOGY
- Pathology of nonalcoholic fatty liver disease
- (2010) Elizabeth M. Brunt Nature Reviews Gastroenterology & Hepatology
- Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease
- (2009) Vincent Wai-Sun Wong et al. HEPATOLOGY
- Galectin-3 Expression and Secretion Links Macrophages to the Promotion of Renal Fibrosis
- (2008) Neil C. Henderson et al. AMERICAN JOURNAL OF PATHOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More